David Fajgenbaum, Associate Professor of Medicine at University of Pennsylvania School of Medicine, Co-Founder and President at Every Cure, shared a post on LinkedIn:
“A study of more than 10,000 cancer patients uncovered something that could change how we think about one of the world’s most popular drugs.
Researchers found that patients taking a certain medication were significantly less likely to see 4 different cancer progress by 30-50%.
So what was the drug?
Not chemotherapy.
Not immunotherapy.
Not a breakthrough cancer drug.
It was a class of medications most people know for weight loss: GLP-1 drugs like Ozempic and Wegovy.
Scientists are now investigating whether these drugs may influence cancer through multiple pathways, including reducing inflammation, lowering insulin levels, altering tumor metabolism, and potentially interacting directly with cancer cells.
Now, it’s important to be careful.
These studies don’t prove that GLP-1 drugs are slowing cancer. Most of the evidence is observational, and randomized trials are still needed.
But when a drug developed for one purpose starts showing signals across multiple cancer types, researchers pay attention.
Because some of the most important medical breakthroughs begin with a question nobody thought to ask:
What else can this drug do?
Learn more about this finding.”
Proceed to the video attached to the post.
Other posts featuring David Fajgenbaum on OncoDaily.